SALUS, Ljubljana, d.d.
LLJSE:SALR68.00
EUR
-0.50
(-0.73%)
ISIN
SI0031110453
Return %
Stock
S&P 500
1Y
38.21
14.20
3Y
235.68
81.12
5Y
292.87
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Žiga Hieng
- Full Time Employees
- 723
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Ljubljana Slovenia
- IPO Date
- Aug 13, 1999
- Website
- salus.si
- Similar Companies
- Business
- SALUS, Ljubljana, d.d., through its subsidiaries, operates as a healthcare commercialization, logistics, and distribution company in Central and Eastern Europe. The company distributes a comprehensive portfolio of healthcare products, including prescription pharmaceuticals, generic medicines, hospital medications, and specialty therapeutics for rare diseases; over-the-counter drugs, herbal remedies, and self-care products; medical devices, diagnostic systems, surgical consumables, and orthopedic equipment; dietary supplements, vitamins, and clinical nutrition products; dermocosmetics, personal care items, and hygiene supplies; and veterinary medicinal products and pharmaceutical packaging solutions. In addition to wholesale distribution, the company provides integrated market access and supply chain services, including regulatory affairs, product registration, and pharmacovigilance; pricing and reimbursement consultancy; temperature-controlled warehousing, cold-chain logistics, and inventory management; third-party logistics and pre-wholesale services; field marketing, medical affairs, and commercial representation; and specialized retail store management for medical and orthopedic supplies. The company serves community and hospital pharmacies, primary healthcare centers, general and specialized hospitals, clinics, residential elderly care homes, veterinary practices, and retail consumers across 18 markets in Central and Eastern Europe. Its direct operational footprint spans subsidiaries in Slovenia, Croatia, Serbia, Bosnia and Herzegovina, North Macedonia, Albania, Montenegro, Lithuania, and the Czech Republic, alongside distribution partnerships in Poland, Slovakia, Hungary, Bulgaria, Kosovo, and Romania. Key operating subsidiaries within the group include SALUS, Veletrgovina, d.o.o., Sanolabor, d.d., and SALUS International d.o.o. SALUS, Ljubljana, d.d. was founded in 1969 and is headquartered in Ljubljana, Slovenia. In recent strategic developments, SALUS, Ljubljana, d.d. has advanced its regional consolidation and commercial expansion through acquisitions, new market entries, and commercialization agreements. In June 2026, the company entered into a share purchase agreement to acquire a 100% equity stake in Farmedica d.o.o., a Slovenian distributor specializing in natural over-the-counter medicines representing brands such as Prospan, A.Vogel, and Isla, for approximately €21.6 million. In October 2025, Salus completed the acquisition of Slovenian pharmaceutical and medical wholesaler Farmadent d.o.o. and its subsidiary Gopharm d.o.o. for €8.46 million to consolidate its wholesale supply chain operations. In July 2026, the group established a new direct subsidiary, SALUS Prague s.r.o., to support commercialization services and market expansion in the Czech Republic. Additionally, in May 2026, Salus entered into a strategic commercial agreement with Oncopeptides AB to manage market access and regional distribution for the multiple myeloma treatment Pepaxti across Central and Eastern Europe.